Takeda HQ

Evotec and Takeda enter into multi therapeutic area collaboration

pharmafile | September 24, 2019 | News story | Manufacturing and Production, Research and Development  

Evotec have announced a strategic, multi-year drug discovery collaboration with Takeda, with both companies aiming to establish at least five drug discovery programmes, with a goal of Evotec delivering clinical candidates for Takeda to pursue into clinical development.

The collaboration, estimated to be worth around $850 million, combines Evotec’s ability to effectively drive fully integrated drug discovery programmes with Takeda’s strategic insights into transformative therapeutic approaches areas.

The specific therapeutic areas being investigated are: Oncology; gastroenterology; neuroscience and rare diseases.

Under the terms of the agreement Takeda will pay Evotec an undisclosed fee to gain access to its platforms. Additionally Evotec is eligible to receive pre-clinical, clinical and commercial milestones that can total in excess of $170 million per programme as well as tiered royalties on future sales.

Steve Hitchcock, Global Head of Research at Takeda, said: “Collaborating with world-class drug discovery partners like Evotec is central to our model for discovering and developing transformative medicines.

“Takeda has a long history of working with Evotec and is confident in Evotec’s capabilities”

Dr Craig Johnson, Chief Operating Officer at Evotec added: “We are pleased to enter into another collaboration with Takeda, whose values are aligned with Evotec’s, including a shared commitment to translating highest quality science into highly innovative medicines.

“We believe this collaboration will be very fruitful for both parties and we are excited to combine our resources and skills to produce novel therapies.”

Nik Kiran

Related Content

No items found

Latest content